News

Christina Y. Weng, MD, MBA discussed what attendees, both virtually and in-person, can expect from this year's Women in Ophthalmology Summer Symposium meeting in Carlsbad, California. The meeting will take place August 22-25, 2024.

The WIO Summer Symposium offers attendees a chance to network, build practice management skills, and plan to reach new goals and milestones in their career.

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.

According to the company, the priority review voucher would be issued upon approval of OPGx-LCA5.

According to the company, the pre-clinical safety and efficacy studies of its product have yielded positive results in 3 internationally recognized labs in India, Singapore and the United States.

PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 for intravitreal treatment of geographic atrophy (GA).

The growing body of evidence that suggests that maintaining adequate levels of vitamin D may be beneficial for preventing and managing RVO.

In English and Spanish TV and radio spots, the public is urged to protect their vision from preventable blindness and vision loss by seeking care from a retina specialist at the first sign of retinal disease.

The Australian Society of Ophthalmologists hosted its inaugural Eye Surgery Showcase, where participants learned how ophthalmologists and the medical technology industry are working together to save the sight of Australians.

EC-104 is a novel intravitreal (IVT) corticosteroid implant with intended 6 months durable drug release for the treatment of DME.

The NIH-funded study finds lack of coverage, copays, restrictive policies barriers to vital eye care for adults.

The LIGHTHOUSE study a Phase I/II, open-label, dose-escalation and dose-expansion clinical trial is currently investigating the safety and tolerability of ASTN-201 for XLRS.

Researchers noted that patients with sickle cell disease had an increased risk of developing any retinal vascular occlusion.

Tim Cherry, PhD, and Debarshi Mustafi, MD, PhD, have been awarded a $150,000 Clinical & Research Synergy Pilot Award from Seattle Children’s Research Institute to determine the genetic causes of unsolved inherited retinal diseases.

The authors explained that estimating the number of such visits in the US may help guide research and clinical efforts to optimize outcomes.

According to the company, the FDA approval strengthens its biosimilar position in the US market.

Researchers conducted a retrospective cohort study that included adult patients 18 years and older who underwent primary repair of uncomplicated rhegmatogenous retinal detachment at the Wilmer Eye Institute from January 2008 to December 2018.

The CPT code is the first to report photobiomodulation therapy in retinal disease.

Researchers from the Shanghai Jiao Tong University School of Medicine developed a deep learning–based model for early identification of myopia, strabismus, and ptosis using 1419 facial photographs from 476 individuals.

Michael Abramoff, MD, PhD, a retina specialist and founder and executive chairman of Digital Diagnostics, points out that much evidence has been collected over the past few decades showing that early detection is key.

The SOL-R clinical trial of is deemed appropriate for use as Ocular Therapeutix’s second adequate and well controlled study of axitinib intravitreal implant.

According to the company, the wearable smart glasses with both vision enhancement and assistance will be introduced at the American Retina Forum National Meeting

LUBT010 is a ranibizumab biosimilar to Lucentis that achieved its primary endpoint in this study.

This clinical milestone marks a new step in treating the condition with a potential long-term benefit.

Investigators at Shandong Normal University in China discovered that ciliary disassembly in photoreceptors is a significant event in the pathogenesis of retinal degeneration.

According to the company, additional data from its Phase 2 ARCHER trial showed both vision protection in standard and low light conditions, and structural protection in regions of the eye key for visual acuity.

The service expands ophthalmological capabilities and enables providers to deliver the gift of sight to patients with complex retinal conditions in Harlem.

Researchers at National Taiwan University Hospital concluded that significant differences were observed in visual acuity, refractive state and myopia rate between patients with inherited retinal disease and the general population.

Kathryn Colby, MD, PhD, described diagnosing and managing these tumors at the National Medical Association annual meeting, Ophthalmology Session in New York.